RT @Hadeel_tak: #دراسة_في_تغريدة أجريت الدراسة لرؤية تأثير Dapagliflozin على مرضى الفشل الكلوي (CKD) مع او بدون امراض القلب Dapagliflozin ه…
#دراسة_في_تغريدة أجريت الدراسة لرؤية تأثير Dapagliflozin على مرضى الفشل الكلوي (CKD) مع او بدون امراض القلب Dapagliflozin هو يستخدم لعلاج type 2 diabetes وأثبتت انه يقلل من خطر الاصابة بالفشل الكلوي ويقلل من نقل مرضى القلب للمستشفى وحالات وفاة القلب. htt
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
It's mostly about the impact on HF - much, much more lethal than boring d CKD. @Kidney_Research @UKKidney
RT @JACCJournals: Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF…
Dapagliflozin reduces cardiac and kidney events in patients with concomitant CHD and heart failure. Learn more in #JACCHF: https://t.co/wcyzRbjI0o #CKD #HeartFailure #Dapagliflozin #type2diabetes #T2D #CardioTwitter https://t.co/37bElXkkFC
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
RT @Darbepoeti_n: DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効か…
DAPA-CKD試験は、CKD患者を対象とした研究ですが、心不全患者も含まれます。この解析によると、ダパグリフロジンは心不全の既往がない患者でも ✓心不全による入院を減らす ことがわかった。心不全の「一次予防」としてもSGLT2iが有効かも?という報告です。凄いですね…! https://t.co/IGsANMTmnA https://t.co/cftjiFlcdW
Open Access UCL Research: Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure https://t.co/173mlrPC2d
RT @ATRIUMRx: Exciting new data from DAPA-CKD trial published in @JACCJournals revealed that dapagliflozin reduces risk of kidney failure a…
RT @DrRaniKhatib: Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CK…
The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF) https://t.co/jjVVtAL7De @JACCJournals https://t.co/1gavIoCAIA
The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF) https://t.co/7XMwVK99rL @JACCJournals https://t.co/dMh2dfVOed
ダパグリフロジンってCKDでも使えるようになったのか。https://t.co/2T0B6hBbi8 https://t.co/Zpkmsuc2uC
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @IHVInews: Results presented at #ESCCongress. Effects of dapagliflozin in patients with CKD with/without HF. John JV McMurray et al. Pub…
RT @UoGHeartFailure: Now online in @JACCJournals #JACCHF ahead of presentation at @escardio #ESC2021 Effects of Dapagliflozin in Patients…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
RT @JACCJournals: #ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFa…
#ESCCongress #JACCHF SimPub: Dapagliflozin reduces cardiac and kidney events in patients with concomitant #CHD & #HeartFailure. https://t.co/rUaVtnQIBb #cvCKD #CKD #Dapagliflozin #AFib #CardioTwitter @UoGHeartFailure https://t.co/71Q4CwT1h1
RT @AndrewJSauer: “Ok kids, put it in the water supply.” Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart F…
RT @coconnormd: Win for patients
RT @IHVInews: Results presented at #ESCCongress. Effects of dapagliflozin in patients with CKD with/without HF. John JV McMurray et al. Pub…
RT @IHVInews: Results presented at #ESCCongress. Effects of dapagliflozin in patients with CKD with/without HF. John JV McMurray et al. Pub…
RT @AndrewJSauer: “Ok kids, put it in the water supply.” Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart F…
“Ok kids, put it in the water supply.” Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure | JACC: Heart Failure @MichaelNassifMD @JavedButler1 @gcfmd @SJGreene_md https://t.co/cVBxEIPIRy
RT @IHVInews: Results presented at #ESCCongress. Effects of dapagliflozin in patients with CKD with/without HF. John JV McMurray et al. Pub…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @IHVInews: Results presented at #ESCCongress. Effects of dapagliflozin in patients with CKD with/without HF. John JV McMurray et al. Pub…
RT @coconnormd: Win for patients
RT @IHVInews: Results presented at #ESCCongress. Effects of dapagliflozin in patients with CKD with/without HF. John JV McMurray et al. Pub…
Win for patients
RT @IHVInews: Results presented at #ESCCongress. Effects of dapagliflozin in patients with CKD with/without HF. John JV McMurray et al. Pub…
Results presented at #ESCCongress. Effects of dapagliflozin in patients with CKD with/without HF. John JV McMurray et al. Published simultaneously in #JACCHF @JACCJournals @coconnormd @mfiuzat @escardio https://t.co/e1Imo8QCpg https://t.co/EPQC1iRpf1
RT @DrRaniKhatib: Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CK…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
Conclusions Dapagliflozin reduced the risk of kidney failure and cardiovascular death/HF hospitalization and prolonged survival in CKD patients with or without type 2 diabetes, independently of history of HF. (A Study to Evaluate t…https://t.co/eitcELXYJS
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @JTLLERGO: ⚠️ DAPA-CKD substudy 📌 Dapagliflozin ⬇️ risk of kidney failure and CV death/HF hospitalization and prolonged survival in CKD…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @ATRIUMRx: Exciting new data from DAPA-CKD trial published in @JACCJournals revealed that dapagliflozin reduces risk of kidney failure a…
RT @ATRIUMRx: Exciting new data from DAPA-CKD trial published in @JACCJournals revealed that dapagliflozin reduces risk of kidney failure a…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…
RT @DrDerekConnolly: DAPA-CKD published in CKD patients (with or without type 2 diabetes), Dapagliflozin reduces the risk of kidney failu…